Abstract
Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL-rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B-precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19-negative monoblastic AML. Complete remission was achieved with myeloid-directed chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1113-1115 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 63 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 Wiley Periodicals, Inc.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Blinatumomab
- CD19
- Infant
- Leukemia
- Lineage
- MLL
Fingerprint
Dive into the research topics of 'Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS